SOFIVA
GENOMICS

SOFIVA GENOMICS

Stock Code 6615

Investor Conference

115 / 06 / 17

Chairman
Yi-Ning Su, MD. Ph.D

小細節 大不同
Details Make Differences

Disclaimer

All statements for investors contain information that represent, other than historical facts, SOFIVA's plans and forward-looking statements are based upon management's current assumptions.

Environmental changes and other important factors could cause actual results to differ materially from those expressed in our statements.

Investors should carefully consider the investment objectives and risks before investing.

SOFIVA - The Dual Operating Strategy

Maternal Fetal Medicine | **Precision Cancer Medicine**

Genetic Screening Category	Servicing Specialty	Target
Reproductive	IVF Center	IVF Embryo Screening
Prenatal	OB-GYN	Pre-pregnant couples Pregnant couples
Newborn	Pediatrics, Neonatology	Child Newborn
Cancer	Cancer-related Specialty	All Target Audience (Pre-Cancer & Patient)
Rare Disease	Genetics-related Specialty	All Target Audience
Precision Medicine	Treatment-related Specialty	All Target Audience

Maternal Fatal Medicine and Precision Cancer Medicine One Stop Service

Reproductive

- PGT-M
- PGT-A
- niPGT-A

Rare Diseases

- Hearing Loss Genetic Test v1.0/v2.0/v3.0
- Achondroplasia
- Osteogenesis Imperfecta
- Duchenne Muscular Dystrophy
- Wilson's Disease
- Marfan Syndrome
- Whole Exon Sequencing Genetic Testing

Prenatal

- NIPS
- Array
- Karyotyping
- Carrier Scan
- SMA Genetic Testing-SMN gene
- Fragile X Genetic Testing-FMR1 gene
- Thalassemia Genetic Testing-HBA,HBB gene
- Folate Metabolism Genetic Testing-MTHFR gene

Cancer

- Cancer Monitor
- Cancer Scan
- Cancer Risk v1.0/v2.0
- HPV Screening

Newborn

- Baby Scan
- Hearing Loss Genetic Screening
- CCHS Genetic Screening
- Congenital CMV Infection Screening
- Atopic Dermatitis Genetic Screening
  -FLG gene

Precision Medicine

- BRCA1/2 Genetic Testing
- HRD Status
- CGP Genetic Test
- Endometrial Cancer Genetic Subtypes
- Prostate Cancer Genetic Testing

SOFIVA GENOMICS

PGT-A

Next-Generation SNP Technology

SOFIVA GENOMICS

IVF Subsidy 3.0 x SNP PGT-A: Expanding Market Reach & Maximizing Success Rates

IVF			Subsidy 3.0	Subsidy 2.0	
Launch Date			2026/4/1~	2023/7/1~	
Eligibility			At least one spouse holds ROC (Taiwan) citizenship Wife is under 45 years old		
First-time Application		<39yrs	Up to NT$ 150,000	Up to NT$ 100,000 / One-time only	
		39~<45yrs	Up to NT$ 130,000		
Subsequent Applications	2nd & 3rd Times	<39yrs	Up to NT$ 100,000	Up to NT$ 60,000 *Low & Middle-Income Households: Up to NT$ 150,000	
		39~<45yrs	Up to NT$ 80,000		
	4th to 6th Times	<39yrs	Up to NT$ 60,000		
		40~<45yrs	X *Limited to 3 times only		
Max. Number of Embryos Permitted for Transfer		<38yrs	Max. 1 Embryo	<36yrs	Max. 1 Embryo
		38~<45yrs	Max. 2 Embryos	36~<45yrs	Max. 2 Embryos

Increased Subsidy Amounts

Extending Age and Embryo Transfer Limits

PGT-A Technology Upgrade +SNP

- ✓ **Value-Added at No Extra Cost:** Aligning with Government Policies to Combat Declining Birthrates
- ✓ **New SNP Technology:** Increasing the Volume of Screenable Embryos
- ✓ **Rescuing Abnormal Fertilization:** Expanding Options for Viable Embryo Transfer
- ✓ **Enhanced Resolution:** SNP Technology Optimizes Analytical Precision
- ✓ **Advanced Ploidy Analysis:** Multi-Parametric Data for Clinical Reference
- ✓ **Higher Precision:** Effectively Boosting Clinical Pregnancy Rates

SOFIVA GENOMICS

Global Collaboration

Partnering with Baylor Genetics (USA)

SOFIVA GENOMICS

Strategic Collaboration. Expanded Services.

- ✓ Internationally Accredited Genetic Testing Laboratory
- ✓ Clinical Support for Medical Decision-Making
- ✓ Integrated Genetic Counseling Services
- ✓ Expertise in Rare Genetic Disease Diagnosis

SOFIVA GENOMICS 慧智基因 × BAYLOR GENETICS



Preconception

Carrier Scan

Prenatal

Non-invasive Prenatal Screening (NIPS)

Rare Diseases

Whole-Exome Sequencing (WES)
Whole-Genome Sequence (WGS)

Increasing Market Penetration of Newborn Genetic Screening

Resilience Against Declining Birthrates

SOFIVA GENOMICS

Declining Birthrates vs. Operational Resilience in Newborn Genetic Screening



1. **Breaking Through the Headwinds:** Despite a cliff-like drop in births, newborn genetic screening revenue has achieved a golden cross with birth numbers.
2. **Robust Performance:** Demonstrating strong growth momentum.
3. **ARPPU Growth:** Continuous growth in premium screening penetration has successfully offset the impact of the declining newborn demographic dividend.

*Note: Q2 2026 revenue and birth numbers include reasonable management estimates for June.

NHI-Reimbursed Testing and Medication

Increasing Market Penetration

SOFIVA GENOMICS

Cancer Treatment Testing Coupled with NHI Testing & Drug Reimbursement Delivers Steady Growth



1. **Unlocking NHI Reimbursement Dividends:** Aligned with the expansion of national NHI testing and drug reimbursement policies, this effectively lowers the out-of-pocket threshold for patients, driving a step-by-step growth in the number of individuals tested.
2. **Strategic Layout in High-Incidence Cancers:** Focusing on gynecological, breast, and urological cancers to provide comprehensive "companion diagnostics" and "precision medication testing."
3. **Strong Consecutive Quarterly Momentum:** Q2 2026 revenue (including June estimates) maintains high-level growth, demonstrating explosive momentum for four consecutive quarters.
4. **Market Penetration Breakthrough:** Penetration rates across major medical institutions continue to climb.

*Note: Q2 2026 revenue includes reasonable management estimates for June.

SOFIVA GENOMICS

Trends and Policies

Development Trends in FHIR and Electronic Health Records

SOFIVA GENOMICS

National Policy Focuses on Genetic Testing and Precision Medicine: Digital Transformation with FHIR



FHIR Features

- ✓ Secure
- ✓ Fast
- ✓ Flexible
- ✓ Integrated

System Optimization

- ✓ Data Collection
- ✓ Cancer Drug Review
- ✓ Perfecting Tracking Systems
- ✓ Enhancing New Drug Evaluation

- ◆Advancing Cancer Prevention and Control Information Systems, Developing AI-Assisted Review
- ◆Integrating International Standards with Real-World Data (RWD) to Accelerate New Drug Evaluation

Source: Ministry of Health and Welfare (MOHW)

FHIR
Fast Healthcare Interoperability Resources

Track Record of Field Validation in Precision Medicine FHIR Scenarios



▲圖1：115年5月14日舉辦「次世代基因定序（NGS）資料收載機制之規劃及建置-成果觀摩會」，由健保署陳亮妤署長(前排中)，臺灣大學楊志新副校長(前排左2)、元鼎診所曾嶽元院長(前排右2)、國衛院邱弘毅所長(前排右1)、奇美醫院李宛珊主任(前排左1)、健保署劉林義主任秘書(後排右3)、國衛院楊奕馨研究員(後排右2)、新光醫院謝忠和資訊長(後排右1)、長庚醫院曹國倩副執行長(後排左3)、行動基因生技公司陳建宏經理(後排左2)、驊智基因公司洪加政總經理(後排左1)，共同參與成果發表。

1. Participated in the NGS data collection mechanism drill organized by the NHIA and NHRI.
2. First Team to Achieve On-Site FHIR Validation: Collaborated with Shin Kong Wu Ho-Su Memorial Hospital to complete clinical FHIR data exchange validation (Field Validation).

檢測結果映射至統一格式

負責將 NGS 檢測數據映射至國衛院定義的統一 JSON Schema 規範。

利用工具進行資料合併轉檔

使用 FHIR API 工具將院內資料與檢測結果整合，轉換為標準 FHIR 格式。

規劃標準格式與提供工具

制定 NGS 標準收載格式，並開發 FHIR 轉換及驗證工具供各界使用。

開設傳輸測試環境

提供穩定安全的傳輸測試環境，確保結構化資料順利收載至健保資料庫。

Sofiva Genomics Digital Healthcare Transformation: Building Data Interoperability Capabilities



1. Standardized Integration: Effectively accelerating reimbursement processing times.
2. Industry Leader: Completed FHIR data exchange validation with top-tier medical centers.
3. Enhancing Client Relationship Depth and Retention.

SOFIVA GENOMICS

Aligning with Government Policies / Optimizing Technology / Expanding Scope of Collaboration: Strengthening Growth Momentum

1	2	3	4	5
Reproductive	Prenatal	Newborn	Cancer Precision Medicine	FHIR Pioneering



- ✓ SNP Upgrade
- ✓ Policy Alignment
- ✓ Collaboration with Baylor
- ✓ Strategic Alliance
- ✓ Boosting Premium Item Penetration
- ✓ Resilient Revenue Against Declining Birthrates
- ✓ Coupled with NHI Reimbursement
- ✓ Increasing Market Penetration
- ✓ Digital Transformation
- ✓ Industry-First Mover

SOFIVA GENOMICS

Operating Performance

SOFIVA GENOMICS

Operational Performance

Statements of Comprehensive Income of last 3 years



	(In Thousands of New Taiwan Dollars)		
	2023	2024	2025
Revenue	466,797	453,312	385,706
Gross Profit	129,908	135,661	99,131
Gross Profit (%)	27.83%	29.93%	25.70%
Opreating Income	-15,882	-3,373	-33,738
Total Non-Opreating Income	24,785	26,988	25,434
Pre-Tax Income	8,903	23,615	-8,304
Net Income	11,923	19,128	-8,855
EPS	0.54	0.86	-0.43

SOFIVA GENOMICS

Revenue Trend：The Last 10 Quarters

(In Thousands of New Taiwan Dollars)



SOFIVA GENOMICS

Revenue Trend：The Last 6 Months



SOFIVA GENOMICS

Investment Performance

(In Thousands of New Taiwan Dollars)			
DIANTHUS CO.,Ltd			
Statements of Comprehensive Income			
	2023	2024	2025
Sales Revenue	695,831	803,024	892,143
Comprehensive Income	142,929	153,057	140,698
Capital Stock	895,000	895,000	895,000
Investment from Sofiva	148,250	148,250	148,250
Shareholding Ratio of Sofiva	16.56%	16.56%	16.56%
Investment Income of Sofiva	23,671	25,348	23,300

SOFIVA GENOMICS

SOFIVA
GENOMICS

慧智基因股份有限公司
www.sofiva.com.tw
T +886-2-2382-6615
F +886-2-2382-6617
100台北市中正區寶慶路27號

Thank you!

小細節 大不同

Details Make Differences